The cases comprise a neighborhood evaluation project initiated by a real estate and construction company on the one hand, and a neighborhood upgrading program initiated by a housing association (in the Netherlands: a non-for-profit market party) on the other hand
p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis
Weight loss from any method, including GLP-1 medications, reduces overall adipose tissue volume but does not fundamentally change the architectural relationship between fat, connective tissue, and skin that creates cellulite's appearance
Frequently Asked Questions How much weight will I gain back if I stop taking semaglutide
This opens the door for generic or biosimilar versions, which bring prices down and make the treatment more widely available
Its exactly what GLP-1 users like me need
